Nanomedicine strategies for cuproptosis: Metabolic reprogramming and tumor immunotherapy.
10.1016/j.apsb.2025.07.007
- Author:
Ruixuan ZHANG
1
;
Yunfei LI
1
;
Hui FU
2
;
Chengcheng ZHAO
3
;
Xiuyan LI
4
;
Yuming WANG
1
;
Yujiao SUN
1
;
Yingpeng LI
1
Author Information
1. School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
2. College of Integrated Chinese and Western Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
3. Experimental Teaching and Practical Training Center, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
4. College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
- Publication Type:Review
- Keywords:
Cancer;
Combination therapy;
Cuproptosis;
Immunotherapy;
Metabolic reprogramming;
Nanomedicine;
Precision therapy;
Tumor microenvironment
- From:
Acta Pharmaceutica Sinica B
2025;15(9):4582-4613
- CountryChina
- Language:English
-
Abstract:
Cuproptosis, a recently discovered form of regulated cell death involving copper ion metabolism, has emerged as a promising approach for tumor therapy. This pathway not only directly eliminates tumor cells but also promotes immunogenic cell death (ICD), reshaping the tumor microenvironment (TME) and initiating robust anti-tumor immune responses. However, translating cuproptosis-based therapies into clinical applications is hindered by challenges, including complex metabolic regulation, TME heterogeneity, and the precision required for effective drug delivery. To address these limitations, nanoparticles offer transformative solutions by providing precise delivery of cuproptosis-inducing agents, controlled drug release, and enhanced therapeutic efficacy through simultaneous modulation of metabolic pathways and immune responses. This review systematically discusses recent advancements in nanoparticle-based cuproptosis delivery systems, highlighting nanoparticle design principles and their synergistic effects when integrated with other therapeutic modalities such as ICB, PTT, and CDT. Furthermore, we explore the potential of cuproptosis-based nanomedicine for personalized cancer treatment by emphasizing strategies for TME stratification and therapeutic optimization tailored to patient profiles. By integrating current insights from metabolic reprogramming, tumor immunotherapy, and nanotechnology, this review aims to facilitate the clinical translation of cuproptosis nanomedicine and significantly contribute to the advancement of precision oncology.
